Zoledronic acid: Past, present and future roles in cancer treatment

Future Oncology

Volumn 1, Issue 2, 2005, Pages 149-159

  Saad, Fred ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

bisphosphonates; breast cancer; lung cancer; myeloma; prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL; BONE; BONE TUMOR; DRUG EFFECT; HUMAN; METABOLISM; METASTASIS; OSTEOLYSIS; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; IMIDAZOLES;

EID: 33646443708     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.2.149     Document Type: Article

References (66)

1. Jemal A, Tiwari RC, Murray T et al.: Cancer statistics, 2004. CA Cancer J. Clin. 54(1), 8-29 (2004)
2. Morrow PKH, Theriault RL: The use of bisphosphonates in breast cancer. Dis. Breast 7(1), 1-14 (2004)
3. Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27(3), 165-176 (2001)
4. Coleman RE: Skeletal complications of malignancy. Cancer 80(8 Suppl.), 1588-1594 (1997)
5. Mercadante S: Malignant bone pain: pathophysiology and treatment. Pain 69 (1-2), 1-18 (1997)
6. Rogers MJ, Watts DJ, Russell RG: Overview of bisphosphonates. Cancer 80(8 Suppl.), 1652-1660 (1997)
7. Fleisch H: Development of bisphosphonates. Breast Cancer Res. 4(1), 30-34 (2002)
8. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P: Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35(1), 87-99 (1983)
9. Schenk R, Eggli P, Fleisch H, Rosini S: Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 38(6), 342-349 (1986)
10. Green JR, Müller K, Jaeggi KA: Preclinical pharmacology of CGP 42 446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9(5), 745-751 (1994)
11. Aredia®: [package insert]. Pamidronate disodium prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.
12. Body JJ, Diel IJ, Lichinitser MR et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14, 1399-1405 (2003)
13. ZOMETA®: (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation (2003).
14. Coleman RE: Zoledronic acid for the treatment of malignant bone disease. Euro. J. Hosp. Pharm. 1, 130-138 (2004)
15. Gnant M, Jakesz R, Mlineritsch B et al.: Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG- 12). Breast Cancer Res. Treat. 88(Suppl. 1), S8-S9. Abstract 6 (2004)
16. Smith MR, McGovern FJ, Zietman AL et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345(13), 948-955 (2001)
17. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169(6), 2008-2012 (2003)
18. Green JR, Rogers MJ: Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev. Res. 55, 210-224 (2002)
19. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G: Human T-cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197(2), 163-168 (2003)
20. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13(4), 581-589 (1998)
21. Rogers MJ, Frith JC, Luckman SP et al.: Molecular mechanisms of action of bisphosphonates. Bone 24(Suppl.), 73S-79S (1999)
22. Russell RG, Rogers MJ, Frith JC et al.: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14(Suppl. 2), 53-65 (1999)
23. Rogers MJ, Gordon S, Benford HL et al.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl.), 2961-2978 (2000)
24. Oliff A: Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta 1423, C19-C30 (1999)
25. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 65, 241-269 (1996)
26. Luckman SP, Coxon FP, Ebetino FH, Russell G, Rogers MJ: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J. Bone Miner. Res. 13(11), 1668-1678 (1998)
27. Dunford JE, Thompson K, Coxon FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296(2), 235-242 (2001)
28. Chen T, Berenson J, Vescio R et al.: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42(11), 1228-1236 (2002)
29. Lin JH: Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2), 75-85 (1996)
30. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J: A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14(9), 1557-1561 (1999)
31. Major P, Lortholary A, Hon J et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19(2), 558-567 (2001)
32. Berenson JR, Vescio R, Henick K et al.: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91(1), 144-154 (2001)
33. Berenson JR, Vescio RA, Rosen LS et al.: A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin. Cancer Res. 7(3), 478-485 (2001)
34. Berenson JR, Rosen LS, Howell A et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91(7), 1191-1200 (2001)
35. Rosen LS, Gordon D, Kaminski M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7(5), 377-387 (2001)
36. Rosen LS, Gordon D, Kaminski M et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 98(8), 1735-1744 (2003)
37. Saad F, Gleason DM, Murray R et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458-1468 (2002)
38. Saad F, Gleason DM, Murray R et al.: Longterm efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879-882 (2004)
39. Rosen LS, Gordon D, Tchekmedyian S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial- the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21(16), 3150-3157 (2003)
40. Rosen LS, Gordon D, Tchekmedyian NS et al.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebocontrolled trial. Cancer 100(12), 2613-2621 (2004)
41. Andersen PK, Gill RD: Coxs regression model for counting processes: a large sample study. Ann Stats. 10(4), 1100-1120 (1982)
42. Major PP, Cook R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am. J. Clin. Oncol. 25(6 Suppl. 1), S10-S18 (2002)
43. Berenson JR, Lichtenstein A, Porter L et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 16(2), 593-602 (1998)
44. Hortobagyi GN, Theriault RL, Lipton A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16(6), 2038-2044 (1998)
45. Theriault RL, Lipton A, Hortobagyi GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebocontrolled trial. J. Clin. Oncol. 17(3), 846-854 (1999)
46. Lipton A, Theriault RL, Hortobagyi GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebocontrolled trials. Cancer 88(5), 1082-1090 (2000)
47. Kohno N, Aogi K, Minami H et al.: A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Proc. Am. Soc. Clin. Oncol. 23(14 Suppl.),43 [Abstract 668] (2004)
48. Lipton A, Zheng M, Seaman J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98(5), 962-969 (2003)
49. Gnant M, Jakesz R, Mlineritsch B et al.: Zoledronic acid inhibits cancer treatmentinduced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatment. The Breast 14(Suppl. 1), S44 [Abstract 103] (2005)
50. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 21(5), 389-406 (1999)
51. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F: Renal failure associated with intravenous diphosphonates. Lancet 1(8322), 471 (1983)
52. Ali SM, Esteva FJ, Hortobagyi G et al.: Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J. Clin. Oncol. 19(14), 3434-3437 (2001)
53. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62(5), 527-534 (2004)
54. Schwartz HC: Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg. 4(3), 251-253 (1982)
55. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA: Costs of prostate cancer, metastatic to the bone, in The Netherlands. Euro. Urol. 43(3), 226-232 (2003)
56. Groot MT, Huijgens PC, Wijermans PJ, Uylde Groot CA: Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev. Pharmacoeconomics Outcomes Res. 4(5), 565-572 (2004)
57. McKiernan JM, Delea TE, Liss M et al.: Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. Proc. Am. Soc. Clin. Oncol. 23, 531 [Abstract 6057] (2004)
58. Delea T, James M, Liss M et al.: Effects of skeletal complications on total medical care costs in women with bone metastases of breast cancer. Bone 34, S86 [Abstract 68] (2004)
59. Delea T, McKiernan J, Liss M et al.: Cost of skeletal complications in patients with multiple myeloma. Presented at: IXth Annual International Workshop on Multiple Myeloma; Salamanca, Spain 2003 [Abstract]
60. Hillner BE, Ingle JN, Chlebowski RT et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21(21), 4042-4057 (2003)
61. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Doubleblind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11(1), 59-65 (1993)
62. Body JJ, Diel IJ, Lichinitzer M et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br. J. Cancer 90(6), 1133-1137 (2004)
63. Shahinian VB, Kuo T-F, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005)
64. Smith MR, Lee WC, Krupsi T et al.: Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer. Proc. Am. Soc. Clin. Oncol. 23, 382 [Abstract 4507] (2004)
65. Carroll PR, Altwein J, Brawley O et al.: Management of disseminated prostate cancer. In:Prostate Cancer: 3rd International Consultation on Prostate Cancer-Paris . Denis L, Bartsch G, Khoury S et al.:, (Eds.), Health Publications, Paris, France, 251-284 (2003)
66. Clezardin P: The antitumor potential of bisphosphonates. Semin. Oncol. 29(Suppl. 21), 33-42 (2002)